Obesity Clinical Trials in Houston, Texas
39 recruitingHouston, Texas
Showing 1–20 of 39 trials
Recruiting
Determinants of Insulin Sensitivity by Age, Sex, Race/Ethnicity, BMI, and PCOS Diagnosis
ObesityInsulin ResistanceHyperinsulinism+2 more
Ali Chappell150 enrolled1 locationNCT05950282
Recruiting
Phase 3
Maridebart Cafraglutide in Heart Failure With Preserved or Mildly Reduced Ejection Fraction and Obesity
ObesityHeart Failure With Preserved Ejection FractionHeart Failure With Mildly Reduced Ejection Fraction
Amgen5,056 enrolled596 locationsNCT07037459
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight and Type 2 Diabetes
Obesity or OverweightType 2 Diabetes Mellitus
Hoffmann-La Roche1,600 enrolled36 locationsNCT07351058
Recruiting
Phase 3
A Clinical Study to Evaluate the Effects of Enicepatide (RO7795068) in Participants With Obesity or Overweight Without Type 2 Diabetes
Obesity or Overweight
Hoffmann-La Roche2,000 enrolled28 locationsNCT07351045
Recruiting
Not Applicable
Negative Pressure Wound Therapy in Healing Abdominal Incision in Obese Patients Undergoing Breast Reconstruction Surgery
ObesityMalignant Breast NeoplasmBody Mass Index Greater Than or Equal to 30+1 more
M.D. Anderson Cancer Center80 enrolled1 locationNCT04003038
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Obesity or Overweight, and Type 2 Diabetes
ObesityOverweight
Eli Lilly and Company1,035 enrolled159 locationsNCT07282600
Recruiting
Phase 3
Efficacy and Safety of Eloralintide (LY3841136) in Participants With Osteoarthritis Knee Pain and Obesity or Overweight
OsteoarthritisOverweight or Obesity
Eli Lilly and Company900 enrolled154 locationsNCT07353931
Recruiting
Phase 3
A Study of Eloralintide (LY3841136) in Participants With Persistent Obesity Who Are Treated With a Weekly Incretin
ObesityOverweight
Eli Lilly and Company900 enrolled178 locationsNCT07392190
Recruiting
Phase 3
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company1,200 enrolled80 locationsNCT06993792
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
ObesityOverweight
Eli Lilly and Company600 enrolled80 locationsNCT06972459
Recruiting
Phase 3
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
ObesityOverweight
Eli Lilly and Company250 enrolled31 locationsNCT07232719
Recruiting
Not Applicable
PATHS-UP Health Behavior Self-monitoring Mobile App for Adolescents
Obesity and Diabetes Mellitus, Type 2Diabetes Prevention
Baylor College of Medicine30 enrolled1 locationNCT06959901
Recruiting
Phase 2
A Study of Macupatide (LY3532226) and Eloralintide (LY3841136), Alone or in Combination, in Adults With Obesity or Overweight and With Type 2 Diabetes
ObesityDiabetes Mellitus, Type 2Overweight
Eli Lilly and Company200 enrolled38 locationsNCT07215559
Recruiting
Phase 2
Aleniglipron Phase 2 in Type 2 Diabetes Mellitus
ObesityWeight LossObese+1 more
Gasherbrum Bio, Inc., a wholly owned subsidiary of Structure Therapeutics50 enrolled17 locationsNCT07400588
Recruiting
Phase 2
Metformin IN Asthma for Overweight and Obese Individuals (MINA)
AsthmaOverweight and ObesityAsthma Chronic
Johns Hopkins University100 enrolled2 locationsNCT06273072
Recruiting
Phase 3
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes
ObesityOverweightType 2 Diabetes
Eli Lilly and Company600 enrolled77 locationsNCT06972472
Recruiting
Not Applicable
Utilization of a Peer-Based Approach for the Promotion of Physical Activity in Inactive Women
Obesity-Related Malignant Neoplasm
M.D. Anderson Cancer Center500 enrolled1 locationNCT05053113
Recruiting
Not Applicable
Adapting and Assessing the Feasibility of a Telehealth Diabetes Prevention Program for Hispanic Adolescents
Obesity and Type 2 Diabetes
Baylor College of Medicine40 enrolled1 locationNCT06943001
Recruiting
Not Applicable
RESET System Pivotal Trial (Rev F)
ObesityDiabetes type2
Morphic Medical Inc.264 enrolled7 locationsNCT04101669
Recruiting
Phase 2
Caloric Restriction and Activity to Reduce Chemoresistance in B-ALL
ObesityB-cell Acute Lymphoblastic Leukemia
Etan Orgel240 enrolled20 locationsNCT05082519